Acadia pharmaceuticals reports third quarter 2023 financial results and operating overview

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced its financial results for the third quarter ended september 30, 2023. “in the third quarter, acadia delivered record product revenue, underscoring the continued strong launch of daybue for the treatment of rett syndrome, and market share growth for the very successful nuplazid franchise,” said steve davis, president and chief executive officer. “in addition to our strong commercial performance, we continue to.
ACAD Ratings Summary
ACAD Quant Ranking